Rapid screening and scaled manufacture of immunogenic virus-like particles in the ALiCE cell-free protein synthesis system

J. Armero Gimenez, A. Schots, R.H.P. Wilbers, C. Williams, Ricarda Finnern

Research output: Contribution to conferencePosterAcademic

Abstract

The recent SARS-CoV-2 pandemic brought renewed attention to the susceptibility of mankind to new and re-emerging diseases, and highlighted the necessity for timely vaccine development to slow the spread of disease. Virus-Like Particles (VLPs) are a very promising alternative to traditional vaccine platforms as they trigger strong and lasting humoral and cellular immune responses in humans, with fewer safety concerns and higher stability than other platforms such as inactivated viruses and RNA vaccines. Here we present the use of ALiCE®, a commercially available tobacco-based cell-free protein synthesis system, to rapidly screen and produce highly immunogenic Hepatitis B-core virus-like particles. We show that VLP production was successfully scaled to 1L, resulting in a 20,000 fold scaling with no loss in yield, leading to the potential production of up to 100,000 vaccine doses.
Original languageEnglish
Publication statusPublished - 17 Jan 2023
EventGlycoBioTec conference - Harnack House in Berlin - the official conference venue of the Max Planck Society. , Berlin, Germany
Duration: 17 Jan 202319 Jan 2023
https://www.mpi-magdeburg.mpg.de/glycobiotec2023

Conference

ConferenceGlycoBioTec conference
Country/TerritoryGermany
CityBerlin
Period17/01/2319/01/23
Internet address

Fingerprint

Dive into the research topics of 'Rapid screening and scaled manufacture of immunogenic virus-like particles in the ALiCE cell-free protein synthesis system'. Together they form a unique fingerprint.

Cite this